Nu-Med Plus Announces Prominent Research Lab to Utilize its New Advanced Nitric Oxide Delivery Product for Study

Nu-Med Plus (OTCQB:NUMD), a medical device leader developing new nitric oxide delivery technology, announces that Dr. Ronald Day, a pediatric cardiologist at the University of Utah, will incorporate the recently developed Nu-Med Plus 100 nitric oxide delivery device into a yet-to-be disclosed research study.

As quoted in the press release:

Dr. Day is a prominent researcher examining, among other studies, nitric oxide to treat children suffering from pulmonary hypertension. Dr. Day recently spoke with The Life Science Report where he discussed the benefits of investigating nitric oxide treatments. Dr. Day is not receiving compensation for utilizing the Nu-Med Plus product.

Nu-Med Plus recently developed the Nu-Med Plus 100 (NMP 100), the world’s first nitric oxide dilution system purpose-built for research. The patent-pending technology utilizes 100% pure nitric oxide from a pressurized tank and dilutes it with precision controls to provide a 1 to 5000 ppm source of nitric oxide for research applications. Dr. Day has already received the research unit from Nu-Med Plus.

Jeff Robins, CEO of Nu-Med Plus, remarked, “The inclusion of our innovative Nu-Med Plus 100 device in this study will further demonstrate how valuable this product is to the nitric oxide research community. We are excited to be working with such an esteemed physician and researcher.”

Click here to read the full press release.